Kwality Pharmaceuticals Ltd

Meeting Details

• Date and Time: 10 August 2026, 4:00 PM IST.
• Type and mode: Knowledge Session (Virtual Interaction) for Investors.
• Organiser: Go India Advisors on behalf of Kwality Pharmaceuticals.
• Participants: Company management (roles not specified) presented.
• Purpose: discuss operations, performance, outlook; no UPSI shared.
• Recording: audio/video recording available; access link provided.

Operating Update

• Sixth unit (hormone) to commence by November 2026.
• Oncology share forecast 25-30% in FY27 due to registrations delays.
• Unit 5 biologicals: Erythropoietin BE pre-clinical complete; trials to start by Nov/Dec 2026.
• ROW registrations targeted in 10-12 geographies; Indian sales immediate.
• Portfolio targets 200-250 products; filings across 60-80 countries; per registration INR 1.5-2.0 million.

Guidance and Outlook

• FY27 revenue expected to cross INR 700-720 crore.
• FY28 EBITDA around 30% at INR1,000 crore revenue.
• FY29 EBITDA target around 30%.
• FY30 revenue target INR1,500 crore; growth 25-30% CAGR.
• FY29 guidance excludes biological and hormone; potential contributions in FY30.

Capex and Projects

• Bio facility: 100L CDSCO approved; 500L installed; CDSCO approval pending.
• BE programs: Ampho B liposomal and Octreotide to finish by Apr-May FY28.
• Leuprolide 45 mg first generic in 75-80% markets; submission by FY28 Q2.
• Algeria biosimilar JV: fill-finish plant; Kwality provides technology; data generation parallel.
• Biosimilar capex: INR150 crores; spend FY28 Q3 to FY29 Q4.

Auditor and Governance

• KPMG to audit; appointment expected by FY27 end.
• Q3/Q4 FY27 appointment aligns with call remarks.

Q&A Highlights

• Biological/hormone not in FY29 guidance; potential in FY30.
• BE filings expected to yield six to seven registrations per quarter.
• FY30 revenue mix: general facility about 40%; LATAM 30-35%; Europe 10-15%.
• Margins may be higher than 30% beyond FY29.

Business Overview

• Core business: injectables, beta-lactams, and complex molecules.
• In-house DSIR-recognized R&D; expanding biologics and hormone capabilities.
• Exports to 70+ markets; diversified global manufacturing and regulatory readiness.

Key Operational Highlights

• FY26 revenue was INR 503 Cr; FY27 guidance raised to 700+ Cr.
• EBITDA margin FY26 about 23.5%; FY27 guidance 27–28%.
• PAT margin FY26 about 13.4%; FY27 target ~15.5%+.
• Hormone Unit 6 capex planned at INR 65 Cr; ~50% incurred.
• First biologic Erythropoietin planned in H1 FY28.
• EU-GMP readiness: 4 of 5 plants approved; expanded regulated access.
• BE programs: 40+ solid-dose BE programs; 3+ BE studies completed in quarter.
• Working capital cycle reduced from 297 to 161 days.
• R&D headcount: 80 scientists; DSIR-recognized.
• Unit 6: hormone facility under construction; 4 of 5 units EU-GMP approved.

Financial Performance

• FY26 revenue: INR 503 Cr; FY27 guidance: 700+ Cr.
• FY26 EBITDA margin: ~23.5%; FY27 target: 27–28%.
• FY26 PAT margin: ~13.4%; FY27 target: ~15.5%+.
• Q1FY27 revenue: INR 162.4 Cr.
• Cash conversion cycle improved to 161 days; strong cash flow.
• Balance sheet: low leverage with healthy debt/coverage; capex headroom.

Capital Structure & Liquidity

• Low leverage and strong coverage; substantial headroom for capex.
• Working capital discipline driving cash generation.
• Export activities with long-cycle receivables managed through scale.

Strategic Priorities & Outlook

• Capex-led expansion across oncology, biologics, and hormones.
• Commercialize first biologic, Erythropoietin, in H1 FY28.
• EU-GMP readiness to unlock regulated markets; 4/5 plants approved.
• Licensing-driven exports to LATAM, Africa, MENA; 70+ markets.
• R&D pipeline: BE optimization and high-margin niche formulations.

Risks & Mitigation

• Regulatory approvals required; EU-GMP readiness ongoing.
• Capex execution risk; strength of balance sheet provides headroom.
• BE program outcomes critical for sustained growth.

Governance & Leadership

• Chairman & MD: Ramesh Arora; Directors: Ajay Arora, Aditya Arora.
• DSIR-recognized in-house R&D; centralized QA/QC across units.
• Audits: 20+ regulatory, customer, and vendor audits completed.

Board approvals

• Standalone and consolidated unaudited Q1 FY27 results approved; quarter ended 30 June 2026.
• Board approved results after Audit Committee review on 10 August 2026.
• Auditors' limited review reports submitted; auditors did not express an audit opinion.

Financial results and guidance

• Consolidated revenue grew 46% YoY to ₹162 crore; EBITDA ₹41 crore; PAT ₹26 crore.
• FY27 guidance raised: revenue ₹700+ crore, EBITDA ₹189-196 crore, PAT ₹109+ crore.

R&D and regulatory updates

• R&D progress: 13 BE studies completed; 15+ BE filings; 15+ product registrations across select markets.
• Biologics: Pembrolizumab pre-clinical batches approved; Erythropoietin progressed to clinical trial.
• Hormone facility on schedule; completion targeted November 2026.
• Regulatory footprint expanded across PIC/S regulators including ANVISA, SFDA, INVIMA, DIGEMID, EU-GMP.

Audit and reporting notes

• Limited audit review; results prepared under Ind AS 34 and Regulation 33 requirements.

Financial performance

• Standalone revenue from operations ₹503.06 crore; Consolidated ₹503.08 crore.
• PAT ₹67.35 crore; up from ₹39.89 crore last year.
• EBITDA margin 19.97%; net profit margin 13.39%.
• PBT ₹89.49 crore; PAT growth ~68.8% YoY.
• Dividend not declared for FY26.
• Net cash from operations ₹16.60 crore; investing ₹34.91 crore.
• Financing cash flow ₹7.04 crore; overall cash decreased ₹11.28 crore.
• DSIR-recognized in-house R&D; ₹60 lakh invested; 40+ BE molecules; three monoclonal antibodies.
• FY27 guidance raised to >₹700 crore; long-term target ₹1,000 crore by FY29.
• EPS ₹64.90; ROE benefited by higher profitability.

Operations & strategy

• Single pharmaceutical-formulations segment; 1,000+ products across 25+ therapies.
• Global footprint: 70+ countries; EU-GMP approved manufacturing; 5 facilities; Unit 6 hormones under construction.
• Bioequivalence program spanning 40+ oral solid molecules; three monoclonal antibodies in development.
• Erythropoietin (Kwalipoietin) BE program pre-clinical done; track for CY2027 launch subject to approvals.
• Significant regulatory audits completed; focus on enhanced regulatory readiness.
• Exhibited presence at 15+ global pharma events to deepen direct customers.
• Strategic capex on hormone facility and oncology/biologics capacity expansion; automation upgrades.

Capital structure & liquidity

• Standalone equity ₹333.37 crore; Consolidated equity ₹329.92 crore.
• Share capital ₹10.38 crore; no change in paid-up capital FY26.
• Long-term borrowings ₹29.40 crore; short-term borrowings ₹101.06 crore.
• Debt-equity ratio ~0.40; interest coverage 9.15x; operating margin 19.97%; net margin 13.39%.
• Current ratio 1.80; cash and cash equivalents ₹0.74 crore.
• Africa subsidiary Kwality Africa Limitada: 51% held; turnover small; year-end loss.

Governance & risk

• Independent director Swanith Kapoor appointed June 2, 2026; term five years.
• Resignations: Kiran Kumar Verma (July 26, 2025); Kartik Kapur (June 2, 2026); Pankaj Takkar and Ravi Shanker Singh.
• Board meetings held: 12; Audit Committee meetings: 5; Nomination & Remuneration: 4; CSR: 1.
• Audit Committee chair changed to Bhavesh Mahajan from Feb 1, 2026; KMP changes noted.
• Secretarial audit by M/s Rishi Mittal & Associates; no qualifications reported.
• Risk management framework in place; ongoing monitoring of regulatory, product, and FX risks.

Dividends, shareholding & related party transactions

• Dividend for FY26: not declared; focus on reinvestment and growth.
• Promoters hold 54.87%; FPIs 2.79%; Indian public 32.30%; NRIs 7.49%.
• Related party transactions reported; arm's-length; remuneration to directors disclosed; policy on RPTs.
• Postal ballot approved appointments of two independent directors (Bedi and Mahajan) on March 28, 2026.

CSR & ESG

• CSR expenditure ₹74.30 lakh; 2% average net profit requirement ₹74.30 lakh.
• One CSR asset created: School building for special children; cost ₹15.75 lakh.
• ₹30.93 lakh utilized from Unspent CSR account in FY2025-26.

Subsidiaries & group

• Kwality Africa Limitada (Mozambique) is 51% owned; turnover and losses modest in year.
• Group consolidated results include Africa subsidiary; Form AOC-1 disseminates subsidiary details.

Audit & governance flags

• Statutory auditors: Vijay Mehra & Co.; no qualifications; term through 2029.
• Secretarial auditors: Rishi Mittal & Associates; five-year term; no qualifications.
• Independent Directors meeting held; declarations of independence obtained; compliance with governance norms.

Book closure details

• Book closure for 43rd AGM: 25 August 2026 to 31 August 2026 (inclusive).
• Record date for E-voting: 24 August 2026.
• Cut-off date for sending AGM notice: 31 July 2026.

Dematerialisation status

• Dematerialisation requests processed and confirmed to depositories.
• Securities dematerialised listed on the stock exchange where existing securities are listed.
• Physical certificates dematerialised mutilated and cancelled; depository name substituted as registered owner within 15 days.

Trading Window Update

• Trading window closes from July 1, 2026, until 48 hours after unaudited Q1 FY ended June 30, 2026.